CN112870185A - Medicine for treating or preventing cervical cancer of human, preparation method and application - Google Patents
Medicine for treating or preventing cervical cancer of human, preparation method and application Download PDFInfo
- Publication number
- CN112870185A CN112870185A CN202110208623.8A CN202110208623A CN112870185A CN 112870185 A CN112870185 A CN 112870185A CN 202110208623 A CN202110208623 A CN 202110208623A CN 112870185 A CN112870185 A CN 112870185A
- Authority
- CN
- China
- Prior art keywords
- parts
- trimethoxy
- cervical cancer
- compound
- dihydroxyphenanthrene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
A therapeutic methodOr a medicine for preventing human cervical cancer and a preparation method and application thereof, belongs to the technical field of medicines, and particularly relates to a medicine for treating or preventing human cervical cancer based on an interaction signal path and a target mechanism of MDM2-p53 protein and protein, and a preparation method and application thereof. The invention discovers that the action mechanism of the compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene is a novel mechanism based on an interaction signal path and a target point of MDM2-p53 protein and protein. The medicine of the invention has the characteristics of novel action mechanism, no addiction and small dosage, and has the function of inhibiting the growth of Hela cells. IC of Hela cells in 48h50It was 0.42. mu.M. Can cause apoptosis by acting on MDM2-p53 pathway, and simultaneously cause mitochondrial apoptosis.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a medicine for treating or preventing cervical cancer of a human, and a preparation method and application thereof.
Background
By the end of this century, cancer will become the global first killer and the greatest obstacle to human life expectancy extension, as reported by the world health organization (WTO). Nearly 1810 thousands of new cancer cases exist in 2018 all over the world, and the number of deaths caused by cancer reaches 960 thousands. Related departments in China make statistics that 130 million people die of cancer every year, the number of new cases is about 160 million, and the annual economic damage reaches billions of yuan. According to the latest Chinese population cause of death form provided by the national tumor prevention and treatment research office, the death rate of malignant tumors is the second cause of death, and the malignant tumors tend to further rise due to serious pollution of the global environment and changes of dietary life forms. The number of cancer diseases of residents in China city, the first cause of death in the city, and the ranking are as follows: lung cancer, liver cancer, gastric cancer, colon cancer, and esophageal cancer.
The morbidity and mortality of cancer is second only to cardiovascular disease. Oncogene, oncogene suppressor gene discovery, and the theory of apoptosis have been developed, and their understanding has also been carried out from the cellular level to the molecular level. Cancer is related to changes of a plurality of oncogenes and cancer suppressor genes, information transmission and protease activity related to apoptosis are researched, and a new means for treating cancer is hopefully provided. In recent years, some progress is made in the research of the cancer suppressor gene p53, and the target is widely concerned as a target drug for researching and treating cancer. Among them, the MDM2 protein is the most important negative regulator of p53, and is involved in regulating the stability and activity of p53 protein, inhibiting cell growth, inducing apoptosis and regulating cell cycle function. However, the research on the action mechanism of the antitumor drug based on the MDM2-p53 protein interaction signal path and target point is rarely reported.
Disclosure of Invention
The invention aims to provide a medicine for treating or preventing human cervical cancer based on an interaction signal path and a target mechanism of MDM2-p53 protein and protein, and a preparation method and application of the medicine.
In order to realize the purpose, the following technical scheme is adopted:
a method for treating or preventing cervical cancerA medicament, the composition of the medicament comprising: 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene, starch, talcum powder, magnesium stearate, microcrystalline cellulose and cross-linked polyvinylpyrrolidone; wherein, the English name of the main component compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene is as follows: 1,5,6-trimethoxy-2, 7-phenathrenediol with molecular formula C17H16O5The molecular weight is 300.31, and the purity of the product in medicine is more than or equal to 90%.
The structure of the compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene is shown as the formula (I):
the compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene is extracted from plants, traditional Chinese medicinal materials or traditional Chinese medicine decoction pieces containing the compound component or is prepared by a chemical method. The plants, the traditional Chinese medicinal materials or the traditional Chinese medicine decoction pieces are as follows: dried stems of Orchidaceae plant Dendrobium officinale Dendrobii of ficile Kimura et Migo, Orchidaceae plant Dendrobium nobile Lindl, Dendrobium huoshanense C Z Tang et S.J Cheng, Dendrobium drumstick Dendrobii Dendrobium chrysotoxum Lindl or Dendrobium fimbriatum hook. cultivars of Dendrobium florum and fresh or dried stems of similar species of the same genus plant. The chemical preparation method is a structure modification which can synthesize the compound by various chemical methods or improve the solubility or bioavailability of the compound by taking the compound as a parent nucleus by a chemical method without changing the structure of the parent nucleus, and comprises various salification, acidification, alkalization and esterification.
Further, the medicine comprises 1-100 parts by weight of 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene, 0-200 parts by weight of starch, 0-5 parts by weight of magnesium stearate, 0-10 parts by weight of talcum powder, 0-250 parts by weight of microcrystalline cellulose, 0-50 parts by weight of cross-linked polyvinylpyrrolidone, 0-10 parts by weight of sodium carboxymethyl starch and 0-150 parts by weight of mannitol.
A method for preparing a medicament for treating or preventing cervical cancer in a human, comprising the steps of:
uniformly mixing a compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene, fine starch powder, microcrystalline cellulose, cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch, talcum powder and magnesium stearate, granulating and drying to obtain the medicine;
or:
mixing the compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene and mannitol, adding water for injection, stirring for dissolving, adjusting the pH to 9.60-10.0, dissolving, filtering, adding activated carbon into the filtrate according to the volume of 1% of the solution, heating at 70-80 ℃ for 30 minutes, and filtering to obtain the medicine.
In the preparation method, 1-100 parts by weight of 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene, 0-200 parts by weight of starch, 0-5 parts by weight of magnesium stearate, 0-10 parts by weight of talcum powder, 0-250 parts by weight of microcrystalline cellulose, 0-50 parts by weight of cross-linked polyvinylpyrrolidone, 0-10 parts by weight of sodium carboxymethyl starch and 0-150 parts by weight of mannitol; the purity of the 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene is more than or equal to 90 percent.
A medicine for treating or preventing human cervical cancer can be used for treating or preventing human cervical cancer. The application mode is that the medicine is used independently or combined with other medicines or pharmaceutically acceptable excipient to prepare various clinically used medicine dosage forms. The medicament dosage form is oral administration preparation, gel or suppository for cavity and tract administration, and injection for intramuscular or intravenous administration; wherein, the route of cavity administration is vagina, anus or nasal cavity, and the preparation for oral administration is tablet, capsule, granule, sustained release preparation, targeting preparation or dripping pill. The excipient comprises one or the combination of pharmaceutically acceptable adhesive, filler, disintegrant, lubricant, preservative, antioxidant, flavoring agent, aromatic, cosolvent, emulsifier, solubilizer, osmotic pressure regulator or colorant.
The action mechanism of the medicine in preparing the medicine for treating or preventing the human cervical cancer is the interaction signal path and the target point mechanism of the MDM2-p53 protein and the protein. Specifically, 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene has good binding energy with MDM2 protein, and the configuration of the structure also conforms to a pharmacophore model of a MDM2-p53 small molecule inhibitor, so the structure potentially acts on an MDM2-p53 pathway. Because the p53 protein can identify tumor cells, the small molecule inhibitor can be competitively combined with the p53 protein to the MDM2 protein site, releases the wild p53 protein, activates and stabilizes the p53 through acetylation and phosphorylation, plays a role in inducing apoptosis and the like, and realizes the targeting cancer inhibition effect.
The medicine can be used as a medicine reference substance for treating or preventing cervical cancer of human.
The compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene adopts an in vitro culture method screening experiment, and the result shows that: IC of compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene on human cervical carcinoma Hela cells50The value was 0.42. mu.M, IC of positive control cisplatin50IC of paclitaxel with value of 7.84. mu.M50The value was 2.01. mu.M. Compared with a positive control drug, the compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene has a very good killing effect on human cervical cancer cells. Therefore, the compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene is an anticancer active ingredient, and a new antitumor pharmaceutical preparation is prepared by using the compound.
The invention has the beneficial effects that:
the invention discovers that the action mechanism of the compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene is a new mechanism based on an interaction signal path and a target point of MDM2-p53 protein and protein, provides scientific basis for clinical application of the compound, enables the compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene to be used as an anticancer agent, and has the characteristics of novel action mechanism, no addiction and small dosage.
The compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene has the effect of inhibiting the growth of Hela cells. The inhibition in the concentration range of 0-100. mu.M increases with increasing drug concentration and with increasing duration of action, showing a clear dose and time dependence. IC acting on Hela cells50It was 0.42. mu.M.
The compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene can cause apoptosis by acting on an MDM2-p53 pathway, and is accompanied with the occurrence of mitochondrial apoptosis.
Drawings
FIG. 1 shows the results of Hela cell inhibition experiment by 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene compound in example 5 of the present invention; wherein, A: the inhibition result of the compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene on Hela cells; b: the inhibition effect of the compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene with different concentrations on Hela cells; c: the compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene has an inhibitory effect on Hela cells in different time periods.
FIG. 2 protein expression in example 6 of the present invention.
Detailed Description
The present invention will be described in more detail with reference to the following examples, but the present invention is not limited to these examples.
The BCA working solution and the hypersensitive light-emitting solution adopted in the specific embodiment of the invention are both provided by Shanghai Bintian biotechnology limited company, and the product numbers are P0012S and P0018S respectively; both the separation gel and the concentrated gel were protein electrophoresis gel kits provided by Beijing Dake for the company.
Example 1
A preparation method of a medicine for treating or preventing cervical cancer of a human comprises the following specific steps:
taking 50g of compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene, adding 150g of starch fine powder, uniformly mixing by an equivalent incremental method, adding 5g of talcum powder and 2g of magnesium stearate, uniformly mixing, granulating by 85% ethanol, drying, granulating, pressing into 1000 tablets, 3 times a day, and 2 tablets each time.
Example 2
A preparation method of a medicine for treating or preventing cervical cancer of a human comprises the following specific steps:
taking 50g of compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene, adding 200g of starch fine powder, 10g of talcum powder and 5g of magnesium stearate, uniformly mixing, granulating, drying, encapsulating, and preparing into 1000 granules, 3 times a day, 2 tablets each time.
Example 3
A preparation method of a medicine for treating or preventing cervical cancer of a human comprises the following specific steps:
taking 100g of compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene, adding 250g of microcrystalline cellulose and 50g of crosslinked polyvinylpyrrolidone, mixing uniformly, adding 90% ethanol for granulation, drying, granulating, adding 10g of sodium carboxymethyl starch and 5g of magnesium stearate, mixing uniformly, pressing into 1000 tablets, and taking 1 tablet 1 time per day 3 times.
Example 4
A preparation method of a medicine for treating or preventing cervical cancer of a human comprises the following specific steps:
taking 50g of compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene and 150g of mannitol, adding 2000mL of water for injection, stirring and dissolving, adjusting the pH to 9.60-10.0 by using 1M NaOH solution, stirring and dissolving, filtering, adding activated carbon into filtrate according to the volume amount of 1% solution, heating at 70-80 ℃ for 30 minutes, roughly filtering, washing pipelines and containers with 400mL of water for injection, adding water to 2500mL, filtering the liquid medicine by using a 0.22 mu M sterile filter, filling, freeze-drying, plugging and rolling a cover to prepare 1000 bottles.
Example 5
Screening of MTT in vitro antitumor Activity
1.1 Experimental methods
Selecting Hela cells with good logarithmic growth phase state, preparing into single cell suspension with pancreatin digestive juice 0.25%, and adjusting cell density to 0.5 × 10 by cell counting4Each/ml, inoculated into a 96-well plate, a drug concentration group, a positive control group, cisplatin and paclitaxel, the concentration of which is set to be 3.125 mu M, 6.25 mu M, 12.5 mu M, 25 mu M, 50 mu M and 100 mu M, and a 0.2% (v: v) DMSO control group is designed, each group is provided with 5 multiple wells, 100 mu l of cell suspension is added into each group, the inoculated 96-well plate is placed at 37 ℃ and 5% CO2Culturing in an incubator overnight, and administering after the cells adhere to the wall. Abandoning the old culture medium, adding 100 μ l of drugs with different concentrations into the drug-adding group, adding 100 μ l of cisplatin with different concentrations into the positive control group, and adding 100 μ l of culture medium into the blank control group. Placing at 37 deg.C and 5% CO2After further culturing in the incubator for 24h and 48h, observing cell morphology under an inverted microscope, adding 10 μ l of MTT stock solution into each well, standing at 37 deg.C and 5% CO2After further 2 hours of incubation in the incubator, the old medium was discarded, 150. mu.l of DMSO was added to dissolve formazan crystals, and the OD value at a wavelength of 490nm was measured using a microplate reader.
1.2 results of the experiment
The screening result of the antitumor activity shows that the compoundThe 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene compound has very strong inhibition effect on Hela tumor cells, and the IC of the compound is 48h as shown in Table 150The value was 0.42. mu.M. As shown in figure 1, in Hela cell drug intervention for 48h, morphological observation under a microscope shows that the compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene causes obvious cell shrinkage, the cell number is reduced, and the compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene can obviously inhibit Hela cell proliferation and is in a concentration and time-dependent relationship.
TABLE 1 Effect of the Compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene on the Activity of Hela cells
1.3 conclusion
The compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene has the effect of inhibiting the growth of Hela cells, and acts on IC of the Hela cells for 48 hours50It was 0.42. mu.M.
Example 6
Protein imprinting (Western Blot analysis)
1 method of experiment
1.1 extraction of Total cellular protein
(1) Cell culture: collecting Hela cells with good log phase state, digesting with pancreatin to obtain single cell suspension, and mixing at 15 × 104One/well was inoculated in a six-well plate and placed in an incubator overnight. When the cells grow to 60% -70%, the medicine is added, the concentration of the medicine is set to be 3.125 mu M, 6.25 mu M and 12.5 mu M, and the control group is DMSO with the same volume.
(2) Collecting cells: after 48h of drug intervention, taking out a six-hole plate, removing the supernatant, washing with cold PBS for 2 times, removing PBS, adding 500 μ l of pancreatin for digestion, adding a culture medium to stop digestion, transferring to a 15ml centrifuge tube, centrifuging at 4 ℃ for 5min at 1000rpm, removing the supernatant, adding cold PBS, blowing, beating, uniformly mixing, centrifuging at 4 ℃ for 5min at 1000rpm, removing the supernatant, adding 1ml of PBS, blowing uniformly, transferring to a 1.5ml EP tube, and centrifuging at 4 ℃ for 15min at 7.0 XG.
(3) Cell lysis: after centrifugation, the supernatant was discarded, the total volume of cell lysate was prepared in advance according to the number of cells, 100:1:1 cell lysate (volume ratio: RIPA: PMSF: phosphatase inhibitor: 100:1:1) was added to each sample, mixed with a magnetic stirrer, and lysed on ice. After the cracking is finished, the protein is completely cracked by using the energy of 70 percent of an ultrasonic instrument for ultrasonic processing. Centrifugation was performed after sonication at 12 XG for 30min at 4 ℃.
1.2BCA assay concentration
(1)5mg/ml protein standard BSA was pre-diluted to 0.5 mg/ml.
(2) Preparing a standard substance: 8 EP tubes, 0.5mg/ml protein standard formulated was diluted according to the following gradient:
(3) dilution of the test protein (40-fold dilution): mu.l of deionized water was added to 2. mu.l of the protein sample.
(4) According to the number of samples, calculating and preparing a BCA working solution, mixing the solution according to the volume ratio of 50:1 of the reagent A to the reagent B, and preparing the solution for use at 200 mu l per well.
(5) Loading a 96-well plate: 200 mul BCA working solution +20 mul standard substance and protein diluent to be detected are added into each well.
(6) Incubate at 37 ℃ for 30min in the dark.
(7) And (3) measuring the absorbance of each hole under A562nm by using a microplate reader, drawing a standard curve by taking the protein content (mu g) as an abscissa and the absorbance as an ordinate, calculating the protein concentration of the sample, and multiplying the obtained concentration by 40 to obtain the concentration of the current protein sample.
1.3 denaturation of proteins
Adding 5 Xloading buffer solution into protein sample, adding 1/4 of protein sample, mixing, and denaturing at 100 deg.C for 5 min.
1.4 compounding
(1) And (4) loading a plate frame, sealing, adding deionized water, detecting whether glue leaks or not, pouring out the water, and wiping the filter paper dry.
(2) Preparing glue, separating glue A liquid, uniformly mixing B liquid according to the volume ratio of 1:1, concentrating the glue A liquid, uniformly mixing B liquid according to the volume ratio of 1:1, adding 10% APS solution into the separated glue solution, uniformly mixing, pouring into a mold, and adding the separated glue solution to the position 1.5cm away from the top end of the front glass plate or about 0.5cm away from the comb teeth. Adding 10% APS solution into the concentrated glue, mixing, and directly pouring into the upper layer of the separated glue solution. Inserting a comb into the gel, standing for 15-20min, and waiting for gel polymerization.
1.5 electrophoretic preparation and Loading
(1) And (3) installing a device, adding 500ml of 1X electrophoresis liquid, pulling a comb to remove bubbles, and designing a loading pore channel.
(2) And (3) carrying out Marker hole loading: the same volume of Marker as protein was added.
(3) Loading protein sample wells: the loading volume was determined as the amount loaded, 40. mu.g loaded (calculation: 40/stock concentration), and the blank channel was filled with the same volume of 1 × loading.
(4) Electrophoresis, constant voltage 80V, after the bromophenol blue runs through the separation gel, the voltage is adjusted to 120V until the bromophenol blue runs out.
1.6 transfer film
Preparing a membrane transfer solution in advance, taking out a gel plate after electrophoresis is finished, putting the gel plate into a white empty tray filled with 1 multiplied membrane transfer solution, removing concentrated gel without protein by using a wane, preparing a membrane transfer clamp, spreading a layer of sponge on the black clamp, the white clamp and the black clamp respectively, soaking and spreading, adding 4 layers of filter paper respectively, soaking and spreading, carefully putting the cut gel on the black clamp, cutting a PVDF membrane with a corresponding size, putting the PVDF membrane into methanol to activate for 60s, transferring the PVDF membrane onto the gel, spreading, avoiding bubbles, assembling the membrane transfer clamp, (black-to-black and white-to-red), and transferring the membrane for 2h at 200V in ice bath.
1.7 milk sealing
Preparing 5mg/ml skim milk sealing liquid, weighing 5g of skim milk, adding 100ml of membrane washing liquid, and mixing uniformly. And (5) after the membrane conversion is finished, taking out the PVDF membrane, transferring the PVDF membrane into milk sealing liquid, and sealing the PVDF membrane on a shaking table at room temperature for 2 hours.
1.8 washing membranes
And after the milk sealing is finished, putting the PVDF membrane into the membrane washing solution, and washing the membrane for 3 times for 10min each time on a shaking table.
1.9 Primary antibody incubation
After the membrane washing is finished, diluting the antibody, adding primary antibody with the corresponding volume according to the size of the membrane, sealing the membrane by using a plastic packaging membrane, and incubating at 4 ℃ overnight.
1.10 washing of membranes
And taking the membrane out of the primary antibody, recovering the primary antibody, putting the PVDF membrane into the membrane washing solution, and washing the membrane on a shaking table for 3 times, 10min each time.
1.11 incubation with Secondary antibody
After membrane washing, diluting the antibody, adding a secondary antibody with a corresponding volume according to the size of the membrane, sealing the opening with a plastic membrane, and incubating for 2h in a shaking table at room temperature.
1.12 washing membranes
And taking the membrane out of the secondary antibody, recovering the secondary antibody, putting the PVDF membrane into the membrane washing solution, and washing the membrane on a shaking table for 3 times, 10min each time.
1.13 development
Mixing the hypersensitive luminous liquid A and the hypersensitive luminous liquid B in equal volume, gently dripping the mixture on a membrane to enable the developing solution to cover the surface to be developed, and then loading and developing.
2 results of the experiment
As shown in figure 2, MDM2 protein is up-regulated, p53 protein is up-regulated, Bcl-2 anti-apoptosis protein is down-regulated, Mcl-1 protein is down-regulated, and Bax protein changes are not obvious, which indicates that the compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene can act on an MDM2-p53 pathway.
3 conclusion
The compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene can cause apoptosis by acting on an MDM2-p53 pathway.
Claims (9)
1. A medicament for the treatment or prevention of cervical cancer in a human, said medicament comprising: 1-100 parts of 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene, 0-200 parts of starch, 0-5 parts of magnesium stearate, 0-10 parts of talcum powder, 0-250 parts of microcrystalline cellulose, 0-50 parts of cross-linked polyvinylpyrrolidone, 0-10 parts of sodium carboxymethyl starch and 0-150 parts of mannitol; wherein the English name of the compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene is as follows: 1,5,6-trimethoxy-2, 7-phenathrenediol with molecular formula C17H16O5Molecular weight of 300.31 inThe purity of the medicine is more than or equal to 90 percent; the structure of the compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene is as follows:
2. the drug for treating or preventing cervical cancer according to claim 1, wherein the compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene in the drug is extracted from plants, traditional Chinese medicinal materials or traditional Chinese medicinal decoction pieces containing the compound or is prepared by a chemical method; the plants, the traditional Chinese medicinal materials or the traditional Chinese medicine decoction pieces are as follows: dried stems of Orchidaceae plant Dendrobium officinale Dendrobii of ficile Kimura et Migo, Orchidaceae plant Dendrobium nobile Lindl, Dendrobium huoshanense C Z Tang et S.J Cheng, Dendrobium chrysotoxum Lindl or Dendrobium fimbriatum hook. cultivated products of Dendrobium chrysanthum of Orchidaceae and fresh or dried stems of similar species of the same genus plants; the chemical preparation method is a structure modification which can synthesize the compound by various chemical methods or improve the solubility or bioavailability of the compound by taking the compound as a parent nucleus by a chemical method without changing the structure of the parent nucleus, and comprises various salification, acidification, alkalization and esterification.
3. The drug for treating or preventing human cervical cancer according to claim 1, wherein the compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene in the drug acts on IC of Hela cells of human cervical cancer50The value was 0.42. mu.M, IC of positive control cisplatin50IC of paclitaxel with value of 7.84. mu.M50The value was 2.01. mu.M.
4. The drug for treating or preventing human cervical cancer according to claim 1, wherein the mechanism of action of the drug for treating or preventing human cervical cancer is the MDM2-p53 protein-protein interaction signaling pathway and target mechanism.
5. The drug for treating or preventing human cervical cancer according to claim 1, wherein the drug can be used as a drug control for treating or preventing human cervical cancer.
6. The method for preparing a medicament for treating or preventing cervical cancer in a human according to any one of claims 1 to 5, comprising the steps of:
uniformly mixing a compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene, fine starch powder, microcrystalline cellulose, cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch, talcum powder and magnesium stearate, granulating and drying to obtain the medicine;
or:
mixing the compound 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene and mannitol, adding water for injection, stirring for dissolving, adjusting the pH to 9.60-10.0, dissolving, filtering, adding activated carbon into the filtrate according to the volume of 1% of the solution, heating at 70-80 ℃ for 30 minutes, and filtering to obtain the medicine.
7. The method for preparing a medicine for treating or preventing cervical cancer according to claim 6, wherein the 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene is 1-100 parts by weight, the starch is 0-200 parts by weight, the magnesium stearate is 0-5 parts by weight, the talcum powder is 0-10 parts by weight, the microcrystalline cellulose is 0-250 parts by weight, the cross-linked polyvinylpyrrolidone is 0-50 parts by weight, the sodium carboxymethyl starch is 0-10 parts by weight, and the mannitol is 0-150 parts by weight; the purity of the 1,5,6-trimethoxy-2, 7-dihydroxyphenanthrene is more than or equal to 90 percent.
8. The pharmaceutical composition for treating or preventing cervical cancer according to claim 1, which is used for treating or preventing cervical cancer.
9. The use of claim 8, wherein the use is by itself or in combination with other drugs or pharmaceutically acceptable excipients, in the form of various clinically useful pharmaceutical dosage forms; the medicament dosage form is oral administration preparation, gel or suppository for cavity and tract administration, and injection for intramuscular or intravenous administration; wherein, the route of cavity administration is vagina, anus or nasal cavity, and the preparation for oral administration is tablet, capsule, granule, sustained release preparation, targeting preparation or dripping pill; the excipient comprises one or the combination of pharmaceutically acceptable adhesive, filler, disintegrant, lubricant, preservative, antioxidant, flavoring agent, aromatic, cosolvent, emulsifier, solubilizer, osmotic pressure regulator or colorant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110208623.8A CN112870185A (en) | 2021-02-25 | 2021-02-25 | Medicine for treating or preventing cervical cancer of human, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110208623.8A CN112870185A (en) | 2021-02-25 | 2021-02-25 | Medicine for treating or preventing cervical cancer of human, preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112870185A true CN112870185A (en) | 2021-06-01 |
Family
ID=76054328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110208623.8A Withdrawn CN112870185A (en) | 2021-02-25 | 2021-02-25 | Medicine for treating or preventing cervical cancer of human, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112870185A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113384564A (en) * | 2021-06-17 | 2021-09-14 | 沈阳药科大学 | Application of p53 target-based trimethoxy dihydroxy phenanthrene compound in cervical cancer resistance and detection method |
| CN113403362A (en) * | 2021-06-17 | 2021-09-17 | 沈阳药科大学 | Method for detecting effect of 1,5, 6-trimethoxy-2, 7-dihydroxyphenanthrene on HepG-2 cells and application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006089881A1 (en) * | 2005-02-23 | 2006-08-31 | Pierre Fabre Dermo-Cosmetique | Use of phenanthrene derivatives as anti-inflammatory agents, synthesis method and intermediate products |
| CN103265414A (en) * | 2013-05-23 | 2013-08-28 | 南京泽朗医药科技有限公司 | Preparation method of confusarin |
| CN111228407A (en) * | 2020-02-21 | 2020-06-05 | 沈阳药科大学 | Dendrobium officinale extract containing total phenanthrene compounds as well as preparation method and application thereof |
-
2021
- 2021-02-25 CN CN202110208623.8A patent/CN112870185A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006089881A1 (en) * | 2005-02-23 | 2006-08-31 | Pierre Fabre Dermo-Cosmetique | Use of phenanthrene derivatives as anti-inflammatory agents, synthesis method and intermediate products |
| CN103265414A (en) * | 2013-05-23 | 2013-08-28 | 南京泽朗医药科技有限公司 | Preparation method of confusarin |
| CN111228407A (en) * | 2020-02-21 | 2020-06-05 | 沈阳药科大学 | Dendrobium officinale extract containing total phenanthrene compounds as well as preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| BORBALA RETHY ET AL.: "Cytotoxic Phenanthrenes from the rhizomes of tamus communis", 《PLANTA MED.》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113384564A (en) * | 2021-06-17 | 2021-09-14 | 沈阳药科大学 | Application of p53 target-based trimethoxy dihydroxy phenanthrene compound in cervical cancer resistance and detection method |
| CN113403362A (en) * | 2021-06-17 | 2021-09-17 | 沈阳药科大学 | Method for detecting effect of 1,5, 6-trimethoxy-2, 7-dihydroxyphenanthrene on HepG-2 cells and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112870185A (en) | Medicine for treating or preventing cervical cancer of human, preparation method and application | |
| US8853194B2 (en) | Sterol derivatives and their synthesis and use | |
| CN112870186A (en) | Medicine for treating or preventing human liver cancer and preparation method and application thereof | |
| CN115089600B (en) | Application of ophiopogonin D in preparation of rotavirus resistant medicines | |
| CN113925890A (en) | Extraction method of caulis spatholobi extract, caulis spatholobi extract and application thereof | |
| CN102716115A (en) | Pharmaceutical composition | |
| CN102716112A (en) | Pharmaceutical composition capable of resisting HPV (human papillomavirus) infection | |
| CN106924236A (en) | Application of the rcumenol in antineoplastic sensitizer is prepared | |
| CN115192573A (en) | Application of demethyleneberberine hydrochloride in preparation of medicine for treating pulmonary fibrosis | |
| CN111358804B (en) | Application of Cynoside H in preparation of medicine for preventing and treating breast cancer | |
| CN102846592B (en) | Medical compound containing borneol | |
| CN107207451A (en) | For the compound for the cancer for treating human papilloma virus (HPV) induction | |
| CN100515414C (en) | Application of honokiol in preparing medicine for treating acute leukemia | |
| CN108939025B (en) | Application of Xiaoaifei honey paste in preparation of medicine for inhibiting tumor cells | |
| CN115232068B (en) | Compound and preparation method and application thereof | |
| CN113952350B (en) | Application of dihydroartemisinin and gypenoside-L in preparation of antitumor drugs | |
| CN102727483B (en) | Pharmaceutical composition containing curzerene and borneol | |
| CN113750083B (en) | Application of metformin in preparation of medicine for treating hand-foot-and-mouth disease | |
| CN110218174B (en) | Compound and preparation method and application thereof | |
| CN102836150A (en) | Drug combination containing borneol | |
| CN117159560A (en) | Application of cyclovirobuxine D in preparing medicament for treating breast cancer | |
| CN116159067A (en) | Application of cyclovirobuxine D in preparing medicament for treating cervical cancer | |
| CN105663120A (en) | Application of artemisitene in preparation of antitumor drug | |
| CN116531399A (en) | Application of rhizoma polygonati polysaccharide in preparation of medicine for preventing ischemic cerebral apoplexy | |
| CN111925405A (en) | Methylisopyrazine A ring glycosylation derivative and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210601 |